

Ordering Provider:
Test Provider MD

Female Sample Report
123 A Street
Sometown, SC 90266



Collection Dates:
2025-06-12 (U3 U4)
2025-06-13 (U1 U2)

Hormone Testing Summary

● Optimal Luteal Range ● Postmenopausal Range ● Out of Range ★ Edge of Range




For an expanded view of results, see pages 2 & 3. For interpretive support, see *About Your Results* pages.

ESTROGEN & PROGESTERONE PRODUCTION





*P4 Serum Equivalent (ng/mL) is a calculated value based on urine pregnanediol.

ESTROGEN METABOLISM




ANDROGEN PRODUCTION




DHEA-S + Etiocholanolone + Androstosterone

ANDROGEN METABOLISM




Cellular DHT Production

Androgens




Progesterone


This result is a weighted average of two progesterone metabolites (below). Progesterone is measured indirectly in urine.



Primary Estrogens



Phase 2 Estrogen Metabolism



The Phase 1 Estrogen Metabolism Pie Chart has been replaced by the 2-OH/16-OH-E1 and 2-OH/4-OH-E1 slider bars (left). See this [video](#) for an explanation with examples. This change aligns the DUTCH report best with published scientific research. See our recent publication in [Menopause](#).



Accession # 01093520

Female Sample Report
123 A Street
Sometown, SC 90266

DOB: 1976-01-01

Age: 49

Sex: Female

Last Menstrual Period:

2025-05-26

Collection Times:

2025-06-13 04:00AM (U1)
2025-06-13 06:00AM (U2)
2025-06-12 03:00PM (U3)
2025-06-12 08:00PM (U4)

Ordering Provider:

Test Provider MD

Sex Hormones & Metabolites


TEST		RESULT	UNITS	LUTEAL*	POSTMENOPAUSAL
Progesterone Metabolites (Urine)					
b-Pregnanediol	Below luteal range	100.0	ng/mg	600 - 2000	60 - 200
a-Pregnanediol	Below luteal range	49.0	ng/mg	200 - 740	15 - 50
Estrogens and Metabolites (Urine)					
Estrone (E1)	High end of luteal range	24.01	ng/mg	12 - 26	1.0 - 7.0
Estradiol (E2)	High end of luteal range	4.00	ng/mg	1.8 - 4.5	0.2 - 0.7
Estriol (E3)	High end of luteal range	16.0	ng/mg	5 - 18	0.6 - 4.0
2-OH-E1	Below luteal range	3.58	ng/mg	5.1 - 13.1	0.3 - 2.0
4-OH-E1	Within luteal range	1.20	ng/mg	0 - 1.8	0 - 0.3
16-OH-E1	Above luteal range	2.80	ng/mg	0.7 - 2.6	0.2 - 0.6
2-Methoxy-E1	Below luteal range	1.35	ng/mg	2.5 - 6.5	0.3 - 1.4
2-OH-E2	Within luteal range	0.74	ng/mg	0 - 3.1	0 - 0.52
4-OH-E2	Within luteal range	0.41	ng/mg	0 - 0.52	0 - 0.12
Total Estrogen	Within range	54.1	ng/mg	35 - 70	3.5 - 15
Metabolite Ratios (Urine)					
2-OH / 16-OH-E1 Balance	Below range	1.28	ratio	2.69 - 11.83	
2-OH / 4-OH-E1 Balance	Below range	2.98	ratio	5.4 - 12.62	
2-Methoxy / 2-OH Balance	Below range	0.38	ratio	0.39 - 0.67	
Androgens and Metabolites (Urine)				Range	
DHEA-S	Below range	16.0	ng/mg	20 - 750	
Androsterone	Within range	1195.0	ng/mg	200 - 1650	
Etiocholanolone	Within range	474.6	ng/mg	200 - 1000	
Testosterone	Within range	7.16	ng/mg	2.3 - 14	
5a-DHT	Within range	6.2	ng/mg	0 - 6.6	
5a-Androstanediol	Above range	32.0	ng/mg	6 - 30	
5b-Androstanediol	Within range	42.6	ng/mg	12 - 75	
Epi-Testosterone	Within range	8.6	ng/mg	2.3 - 14	

* The Luteal Range represents the expected premenopausal luteal range, collected menstrual cycle days 19-22 of a 28-day cycle. If your patient noted taking oral progesterone, the reference range represents the expected range on 100 - 200 mg of oral micronized progesterone (OMP). The ranges in the table below represent ranges in other times of the cycle your patient may have collected, such as follicular or ovulatory phases.

ADDITIONAL NORMAL RANGES	FOLLICULAR	OVULATORY	ON ORAL PG
b-Pregnanediol	100 - 300	100 - 300	2000 - 9000
a-Pregnanediol	25 - 100	25 - 100	580 - 3000
Estrone (E1)	4.0 - 12.0	22 - 68	N/A
Estradiol (E2)	1.0 - 2.0	4.0 - 12.0	N/A

About Your Results | Estrogen & Progesterone

The following *About Your Results* sections include key DUTCH report elements from page 1 to aid your interpretation.



Estrogen-related Patient or Sample Comments:

- The patient reports regular menstrual cycles.
- The patient reported collecting samples on Cycle Day 18. Estrogen and progesterone levels would be expected to reflect luteal phase values if the onset of her next menstrual cycle occurred 4-10 days after sample collection.

#1. Assess estrogen levels given the patient's reproductive status

- Estradiol (the most potent estrogen) is **4.00 ng/mg**, which is within the optimal luteal range, but toward the higher end. If paired with other elevated estrogen markers, poor estrogen metabolism, or suboptimal progesterone, this may contribute to estrogen excess symptoms.

#2. Assess progesterone levels given the patient's reproductive status


- The progesterone serum equivalent is **1.30 ng/mL**, which is below the optimal luteal range. This may indicate the patient did not ovulate or, if the patient ovulated, progesterone is suboptimal. Confirm that the patient's samples were collected in the luteal phase to interpret this result.
- The balance between progesterone and estradiol is assessed in the luteal phase, which is confirmed when progesterone is in the green range on the dial. In this case the progesterone is below the luteal range, so it is important to confirm sample timing relative to menses. The b-pregnanediol/E2 ratio is **25.0**, which is below the optimal range of 100-500. This can indicate progesterone may be suboptimal relative to estradiol, if peak progesterone was captured.

#3. Assess 2-OH preference in phase 1 estrogen metabolism

- The 2-OH/16-OH-E1 is higher than only **11.0%** of the population, which is below the optimal range. This indicates a preference for the estrogenic 16-OH-E1 metabolite compared to the beneficial 2-OH-E1 metabolite. The 16-OH preference may be associated with estrogenic activity and high estrogen symptoms.
- The 2-OH/4-OH-E1 is higher than only **4.00%** of the population, which is below the optimal range. This indicates a preference for the potentially genotoxic (DNA damaging) 4-OH-E1 metabolite compared to the beneficial 2-OH-E1 metabolite. The 4-OH preference may be associated with oxidative stress.

#4. Assess methylation of reactive 2-OH catechol estrogens

- The methylation activity is higher than only **17.0%** of the population, which is below the optimal range. This indicates slow estrogen methylation, which inhibits estrogen detoxification.



Androgen-related Patient or Sample Comments:

- Women aged 41-55 may fall within or below the optimal premenopausal androgen range. Symptoms and other androgen levels should be considered when assessing whether these levels are appropriate for the patient. This age range includes the typical transition through perimenopause and menopause, which can vary significantly between individuals. Therefore, androgen results in this group should be interpreted with both premenopausal and postmenopausal reference ranges in mind.

#1. Assess adrenal androgen levels (Total DHEA)

- The total DHEA production is **1,686 ng/mg**, which is within the optimal premenopausal range. These three metabolites represent about 75% of adrenal androgens, which are typically the source of more than half a woman's circulating testosterone and a significant portion of circulating estrogens.

#2. Assess testosterone levels

- Testosterone is **7.2 ng/mg**, which is within the optimal premenopausal range. In most cases, 25-50% of testosterone comes from the ovaries and the rest from adrenal androgen production (see above). Testosterone is a strong androgen and can become 3x more potent if metabolized to 5a-DHT (see below) within target tissue.

#3. Assess cellular production of 5a-DHT via 5a-androstenediol

- 5a-Androstenediol is **32.0 ng/mg**, which is above the range for women of any age. 5a-Androstenediol reflects the tissue activity of 5a-DHT (the most potent androgen).

#4. Assess if there is a preference for the more potent alpha metabolism of the androgens

- The 5a-Metabolism of androgens is higher than **94.0%** of the population, which is above the range. This indicates a preference for the more androgenic pathway. If paired with high androgens, this may contribute to androgen excess symptoms.

The previous "About Your Results" pages look at core insights for the DUTCH report shown on the Hormone Testing Summary page, all of which are worth considering for most patients. Next, "Advanced Insights" cover additional features within the DUTCH test that require reviewing the pages after the summary page. These concepts are more complex but can be highly relevant for some patients. Review the concepts and look for patient-specific comments, when notable, in bullets.

ESTROGEN & PROGESTERONE

#1. Assess whether E1, E3, or 16-OH-E1 add more insight into overall estrogenic activity

While E2 is the most potent estrogen, other estrogens - such as estrone (E1), 16-hydroxyestrone (16-OH-E1), and estriol (E3) - also contribute to overall estrogenic activity.

E1 is less potent than E2 but can still impact total estrogenic load and can be converted to E2 as needed. 16-OH-E1 is weaker than E2 but may exert significant estrogenic effects, depending on the tissue in which it is produced. E3 is a weak estrogen with mild estrogenic effects and may have anti-inflammatory properties.

Higher levels of these additional estrogens relative to E2 may enhance overall estrogenic activity, while lower levels may result in reduced estrogenic effects.

#2. Assess if there is a preference for alpha metabolism of progesterone

The slider bar for 5a-metabolism of progesterone metabolites reflects the balance between a-pregnanediol and b-pregnanediol. Most progesterone is typically metabolized to b-pregnanediol, but a-pregnanediol is an active metabolite that can bind to GABA receptors in the central nervous system. A higher result on the 5a-metabolism (P4) slider indicates that available progesterone has a greater potential for impact on GABA receptors.

- 5a-metabolism of progesterone is higher than **74.0%** of the population, which is in the normal range. This indicates that the patient does not have an extreme metabolic preference for either pathway. 5a progesterone metabolites are active on GABA receptors and may impact mood and sleep. This is most relevant when patients have luteal levels of progesterone or higher, and especially relevant for those on oral/sublingual progesterone.

#3. Assess estrogen clearance through phase 1 and 2

By looking at the parent estrogens (E1, E2) and their breakdown products (2OH, 4OH, 16OH, and 2MeOHE1), we can see how quickly estrogen is being metabolized. If the parent estrogens are higher than the breakdown products, it means estrogen is clearing more slowly, which increases risk of estrogen excess symptoms. Balanced levels show normal clearance, while lower parent estrogens compared to breakdown products suggest faster clearance, decreasing the risk of estrogen excess symptoms.

ANDROGENS

#1. Assess if the DHEA-S is relatively lower than the Total DHEA

DHEA-S is primarily produced in the adrenals through sulfation. Inflammation can inhibit sulfation, lowering DHEA-S levels and diverting DHEA metabolism toward 5a- and 5b-reductase pathways, resulting in higher etiocholanolone (5b-metabolite) and androsterone (5a-metabolite) levels relative to DHEA-S. Review the patient's results to assess if this pattern is present.

#2. Assess the androgen pattern to determine if urine testosterone may not accurately reflect systemic levels (UGT2B17 deletion)

- This advanced topic is only relevant if the patient has low testosterone (T) with other specific patterns of androgen metabolites, especially when levels of Epi-T (see page 3) are much higher than T on the DUTCH Test. In patients that do have a suspicious pattern, urine testosterone may underestimate true testosterone levels. This patient's results do NOT indicate a reason to be suspicious of the urine testosterone levels. For information on this topic, see this [video](#)

About Your Results | Advanced Insights (continued)

#3. While 5a-androstanediol best represents cellular 5a-DHT production, assess if 5a-DHT offers additional insight into androgenic activity

5a-DHT is testosterone's active metabolite and is three times more potent than testosterone. If elevated it may contribute to androgen excess symptoms. Research shows 5a-androstanediol may be a better marker of 5a-DHT tissue activity, but the 5a-DHT result may provide additional insight. Review the 5a-DHT result in context of other androgens and androgenic symptoms for a deeper understanding of the androgen results.

Thank you for choosing DUTCH for your functional endocrinology testing needs!

Please review our DUTCH resources for information on reading the DUTCH test:

For DUTCH Overviews and Tutorials, click here: <https://dutchtest.com/tutorials>

To view the steroid pathway chart, click here: <https://dutchtest.com/steroid-pathway>

Finally, please review the patient's results along with their requisition form. It is designed to capture relevant medications, symptoms, diagnoses, sample collection, and notes that may be helpful in interpreting the results.

Additional Comments

Reference Range Percentiles

Reference ranges are developed by testing thousands of healthy individuals, while excluding results from outliers or those on impactful medications. A percentile approach is applied, as is done with most labs. Classic reference ranges use the 95th percentile as the upper end of range and the 5th percentile as the lower end of range. Our DUTCH ranges uses the percentiles found in the table below. We feel these ranges reflect the more optimal range sought in functional medicine practices. The table below shows the percentiles used for the reference range of each analyte on the DUTCH report:

Female Reference Ranges (Updated 10.15.2025)									
	Low%	High%	Low	High		Low%	High%	Low	High
b-Pregnanediol	20%	90%	600	2000	Cortisol U0 (Mid-Sleep)	0	90%	0	15
a-Pregnanediol	20%	90%	200	740	Cortisol U1 (Waking)	20%	90%	10	50
Estrone (E1)	20%	80%	12	26	Cortisol U2 (+2 Hours)	20%	90%	30	130
Estradiol (E2)	20%	80%	1.8	4.5	Cortisol U3 (Dinner)	20%	90%	7	30
Estriol (E3)	20%	80%	5	18	Cortisol U4 (Bedtime)	0	90%	0	14
2-OH-E1	20%	80%	5.1	13.1	Cortisone U0 (Mid-Sleep)	0	90%	0	14
4-OH-E1	0	80%	0	1.8	Cortisone U1 (Waking)	20%	90%	40	120
16-OH-E1	20%	80%	0.7	2.6	Cortisone U2 (Morning)	20%	90%	90	230
2-Methoxy-E1	20%	80%	2.5	6.5	Cortisone U3 (Dinner)	20%	90%	32	110
2-OH-E2	0	80%	0	3.1	Cortisone U4 (Bedtime)	0	90%	0	55
4-OH-E2	0	80%	0	0.52	Cortisol Clearance Rate (CCR)	20%	80%	6	12.5
2-16-ratio	20%	80%	2.69	11.83	Melatonin (6-OHMS)	20%	90%	10	85
2-4-ratio	20%	80%	5.4	12.62	8-OHdG	0	90%	0	5.2
2Me-2OH-ratio	20%	80%	0.39	0.67	Methylmalonate	0	90%	0	2.5
DHEA-S	20%	90%	20	750	Xanthurenate	0	90%	0.12	1.2
Androsterone	20%	80%	200	1650	Kynurenate	0	90%	0.8	4.5
Etiocholanolone	20%	80%	200	1000	b-Hydroxyisovalerate	0	90%	0	12.5
Testosterone	20%	80%	2.3	14	Pyroglutamate	10%	90%	28	58
5a-DHT	0	80%	0	6.6	Indican	0	90%	0	100
5a-Androstenediol	20%	80%	6	30	Homovanillate	10%	95%	3	11
5b-Androstenediol	20%	80%	12	75	Vanilmandelate	10%	95%	2.2	5.5
Epi-Testosterone	20%	80%	2.3	14	Quinolinate	0	90%	0	9.6
a-THF	20%	90%	75	370	Calculated Values				
b-THF	20%	90%	1050	2500	Total DHEA Production	20%	80%	500	3000
b-THE	20%	90%	1550	3800	Total Estrogens	20%	80%	35	70
					Metabolized Cortisol	20%	90%	2750	6500
					24hr Free Cortisol	20%	90%	65	200
					24hr Free Cortisone	20%	90%	220	450
% = population percentile: Example - a high limit of 90% means results higher than 90% of the women tested for the reference range will be designated as "high."									